Heterogeneity of psychosis risk within individuals at clinical high risk: A meta-analytical stratification

JAMA Psychiatry

Volumn 73, Issue 2, 2016, Pages 113-120

  Fusar Poli, Paolo ^a,b   Cappucciati, Marco ^a,c   Borgwardt, Stefan ^d   Woods, Scott W ^e   Addington, Jean ^f   Nelson, Barnaby ^g   Nieman, Dorien H ^h   Stahl, Daniel R ^a   Rutigliano, Grazia ^a   Riecher Rössler, Anita ^d   Simon, Andor E ^d,i   Mizuno, Masafumi ^j   Lee, Tae Young ^k   Kwon, Jun Soo ^k   Lam, May M L ^l   Perez, Jesus ^m   Keri, Szabolcs ⁿ   Amminger, Paul ^g   Metzler, Sibylle ^o   Kawohl, Wolfram ^o   Rössler, Wulf ^o   Lee, Jimmy ^p   Labad, Javier ^q   Ziermans, Tim ^r   An, Suk Kyoon ^s   Liu, Chen Chung ^t   Woodberry, Kristen A ^u,v   Braham, Amel ^w   Corcoran, Cheryl ^x   McGorry, Patrick ^g   Yung, Alison R ^y   McGuire, Philip K ^a   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF BASEL   (Switzerland)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults   (Switzerland)

^j TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k Seoul National University College of Medicine   (South Korea)

^l KWAI CHUNG HOSPITAL   (Hong Kong)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

^o UNIVERSITY HOSPITAL OF PSYCHIATRY ZURICH   (Switzerland)

^p INSTITUTE OF MENTAL HEALTH   (Singapore)

^q Hospital Universitari Parc Taulí   (Spain)

^r LEIDEN UNIVERSITY   (Netherlands)

^s Yonsei University College of Medicine   (South Korea)

^t NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^u MAINE MEDICAL CENTER   (United States)

^v HARVARD MEDICAL SCHOOL   (United States)

^w FARHAT HACHED HOSPITAL   (Tunisia)

^x Och Spine at New York Presbyterian Hospitals   (United States)

^y UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIBLIOGRAPHIC DATABASE; DATA EXTRACTION; FOLLOW UP; HIGH RISK PATIENT; HUMAN; META ANALYSIS (TOPIC); PSYCHOSIS; PUBLICATION; PUBLISHING; SENSITIVITY ANALYSIS; CLASSIFICATION; META ANALYSIS; RISK;

HUMANS; PSYCHOTIC DISORDERS; RISK;

EID: 84957611027     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2015.2324     Document Type: Article

References (60)

1. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull. 1996; 22(2): 283-303.
2. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: A comprehensive state-of-the-art review. JAMA Psychiatry. 2013; 70 (1): 107-120.
3. Fusar-Poli P, CappucciatiM, Rutigliano G, et al. At risk or not at risk? Ameta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction.World Psychiatry. 2015; 14(3): 322-332.
4. Kempton MJ, Bonoldi I, Valmaggia L,McGuire P, Fusar-Poli P. Speed of psychosis progression in people at ultra high clinical risk: A complementary meta-analysis. JAMA Psychiatry. 2015; 72(6): 622-623.
5. Fusar-Poli P. The enduring search for Koplik spots of psychosis. JAMA Psychiatry. 2015; 72(9): 863-864.
6. Kapur S, Phillips AG, Insel TR.Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry. 2012; 17(12): 1174-1179.
7. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: Meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012; 69(3): 220-229.
8. Nelson B, Yuen HP,Wood SJ, et al. Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: The PACE 400 study. JAMA Psychiatry. 2013; 70(8): 793-802.
9. Fusar-Poli P, Radua J, Frascarelli M, et al. Evidence of reporting biases in voxel-based morphometry (VBM) studies of psychiatric and neurological disorders. Hum Brain Mapp. 2014; 35 (7): 3052-3065.
10. Fusar-Poli P, Borgwardt S, Valmaggia L. Heterogeneity in the assessment of the at-risk mental state for psychosis. Psychiatr Serv. 2008; 59 (7): 813.
11. Nelson B, Yuen K, Yung AR. Ultra high risk (UHR) for psychosis criteria: Are there different levels of risk for transition to psychosis? Schizophr Res. 2011; 125(1): 62-68.
12. Gross G, Huber G, Klosterkötter J, LinzM. Bonn Scale for the Assessment of Basic Symptoms. Berlin, Germany: Springer-Verlag; 1987.
13. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283 (15): 2008-2012.
14. Yung AR, Yuen HP,McGorry PD, Phillips L, Kelly D, Dell'Olio M, et al. Mapping the onset of psychosis: The Comprehensive Assessment of At Risk Mental States (CAARMS).Aust N Z J Psychiatry. 2005; 39: 964-971.
15. McGlashan TH,Walsh B,Wood SJ. The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-up. New York, NY: Oxford University Press; 2010.
16. Riecher-Rössler A, Aston J, Ventura J, et al. The Basel Screening Instrument for Psychosis (BSIP): Development, structure, reliability and validity. Fortschr Neurol Psychiatr. 2008; 76(4): 207-216.
17. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J. Schizophrenia Proneness Instrument, Adult Version (SPI-A). Rome, Italy: Giovanni Fioriti Editore; 2007.
18. Schultze-Lutter F, Koch E. Schizophrenia Proneness Instrument, Child and Youth Version (SPI-CY). Rome, Italy: Giovanni Fioriti Editore; 2010.
19. Klosterkötter JGG, Huber G, Wieneke A, Steinmeyer EM, Schultze-Lutter F. Evaluation of the Bonn Scale for the Assessment of Basic Symptoms-BSABS as an instrument for the assessment of schizophrenia proneness: A review of recent findings. Neurol Psychiatry Brain Res. 1997; 5: 137-150.
20. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ. 2009; 339: B2535.
21. Nyaga VN, ArbynM, Aerts M. Metaprop: A Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014; 72(1): 39.
22. Newcombe RG. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med. 1998; 17(8): 857-872.
23. Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950; 21: 607-611.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3): 177-188.
25. Harbord R, Higgins J. Metaregression in Stata. Stata J. 2008; 8(4): 493-519.
26. Borenstein M, Hedges L, Higgins J. Introduction to Meta-analysis. Hoboken, NY: John Wiley & Sons; 2009.
27. LipseyM,Wilson D. Practical Meta-analysis. Thousand Oaks, CA: Sage Publications; 2000.
28. Steichen T. Nonparametric Trim and Fill Analysis of Publication Bias inMeta-analysis. Chicago, IL: StataCorp LP; 2001: 10-57.
29. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008; 61 (10): 991-996.
30. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases inmeta-analysis. BMJ. 2001; 323(7304): 101-105.
31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109): 629-634.
32. Harbord R, Harris R, Sterne A. Updated tests for small-study effects inmeta-analyses. Stat Med. 2009; 9(2): 197-210.
33. Lee J, Rekhi G, Mitter N, et al. The Longitudinal Youth at Risk Study (LYRIKS)-an Asian UHR perspective. Schizophr Res. 2013; 151(1-3): 279-283.
34. Winton-Brown TT, Harvey SB, McGuire PK. The diagnostic significance of BLIPS (Brief Limited Intermittent Psychotic Symptoms) in psychosis. Schizophr Res. 2011; 131(1-3): 256-257.
35. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: Predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003; 29(4): 703-715.
36. Schultze-Lutter F, Schimmelmann BG, Ruhrmann S. The near Babylonian speech confusion in early detection of psychosis. Schizophr Bull. 2011; 37(4): 653-655.
37. Fusar-Poli P, Van Os J. Lost in transition: Setting the psychosis threshold in prodromal research. Acta Psychiatr Scand. 2013; 127(3): 248-252.
38. Fusar-Poli P, CappucciatiM, Bonoldi I, et al. Meta-analytical prognosis of brief psychotic episodes: A momentary lapse of reason. JAMA Psychiatry. In press. doi: 10.1001/jamapsychiatry.2015.2313.
39. Fusar-Poli P, Frascarelli M, Valmaggia L, et al. Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study. Psychol Med. 2015; 45(6): 1327-1339.
40. Cornblatt BA, Carrión RE, Auther A, et al. Psychosis prevention: A modified clinical high risk perspective from the Recognition and Prevention (RAP) Program. Am J Psychiatry. 2015; 172(10): 986-994.
41. Kelleher I, Murtagh A, Molloy C, et al. Identification and characterization of prodromal risk syndromes in young adolescents in the community: A population-based clinical interview study. Schizophr Bull. 2012; 38(2): 239-246.
42. Debbané M, Eliez S, Badoud D, Conus P, Flückiger R, Schultze-Lutter F. Developing psychosis and its risk states through the lens of schizotypy. Schizophr Bull. 2015; 41(suppl 2): S396-S407.
43. Rasic D, Hajek T, Alda M, Uher R. Risk of mental illness in offspring of parents with schizophrenia, bipolar disorder, and major depressive disorder: Ameta-analysis of family high-risk studies. Schizophr Bull. 2014; 40(1): 28-38.
44. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995; 311(7003): 485.
45. Lenth R. Some practical guidelines for effective sample-size determination.AmStat. 2001; 55: 187-193.
46. Hoenig J, Heisey D. The abuse of power: The pervasive fallacy of power calculations in data analysis. Am Stat. 2001; 55: 19-24.
47. LevineM, Ensom MH. Post hoc power analysis: An idea whose time has passed? Pharmacotherapy. 2001; 21(4): 405-409.
48. Schultze-Lutter F, Klosterkötter J,Michel C, Winkler K, Ruhrmann S. Personality disorders and accentuations in at-risk persons with and without conversion to first-episode psychosis. Early Interv Psychiatry. 2012; 6(4): 389-398.
49. Fusar-Poli P, Meneghelli A, Valmaggia L, et al. Duration of untreated prodromal symptoms and 12-month functional outcome of individuals at risk of psychosis. Br J Psychiatry. 2009; 194(2): 181-182.
50. Fusar-Poli P, RocchettiM, Sardella A, et al. Disorder, not just a state of risk: Meta-analysis of functioning and quality of life in subjects at high clinical risk for psychosis. Br J Psychiatry. In press.
51. Wiltink S, Velthorst E, Nelson B, McGorry PM, Yung AR. Declining transition rates to psychosis: The contribution of potential changes in referral pathways to an ultra-high-risk service. Early Interv Psychiatry. 2015; 9(3): 200-206.
52. Yung AR, Yuen HP, Berger G, et al. Declining transition rate in ultra high risk (prodromal) services: Dilution or reduction of risk? Schizophr Bull. 2007; 33(3): 673-681.
53. Fusar-Poli P, Schultze-Lutter F, CappucciatiM. The dark side of the moon: Meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull. 2015; (November): 20.
54. Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry. 2007; 68(4): 546-557.
55. van der GaagM, Smit F, Bechdolf A, et al. Preventing a first episode of psychosis: Meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res. 2013; 149(1-3): 56-62.
56. Schultze-Lutter F, Michel C, Schmidt SJ, et al. EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry. 2015; 30(3): 405-416.
57. Fusar-Poli P, Bechdolf A, TaylorMJ, et al. At risk for schizophrenic or affective psychoses? ameta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull. 2013; 39(4): 923-932.
58. Valmaggia LR, Byrne M, Day F, et al. Duration of untreated psychosis and need for admission in patients who engage with mental health services in the prodromal phase. Br J Psychiatry. 2015; 207(2): 130-134.
59. Buchy L, Cadenhead KS, Cannon TD, et al. Substance use in individuals at clinical high risk of psychosis. Psychol Med. 2015; 45(11): 2275-2284.
60. Modinos G, Allen P, Frascarelli M, et al. Are we really mapping psychosis risk? neuroanatomical signature of affective disorders in subjects at ultra high risk. Psychol Med. 2014; 44(16): 3491-3501.